Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

The companies will continue with their exclusive agreements, including for commercialization of their current portfolio The companies will continue with their exclusive agreements, including for commercialization of their current portfolio

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline

CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory study, ENVISION, of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease, including details of the study's goal for diverse enrollment and primary endpoint.

Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®

The company is still dealing with the fallout of a controversial regulatory approval.

Is Biogen a Buy?

The Centers for Medicare and Medicaid may ensure the commercial death of Biogen's controversial Alzheimer's drug. And that leads at least one analyst to wonder if more radical steps need to be taken.

Biogen After the Alzheimer's Drug Debacle: Time to Sell the Parts?

Is Biogen a Buy After the Latest Aduhelm Disaster?

Biogen Inc. (BIIB) closed at $239.30 in the latest trading session, marking a +1.11% move from the prior day.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

As the prospects for its once-promising Alzheimer's drug continue to dim, Biogen Inc. ( BIIB , Financial) is reportedly exploring strategic options, including selling itself or acquiring a smaller bioscience company. The Boston-area biotech has gone so far as to hire Goldman Sachs Group Inc. ( GS , Financial) to put together a roster of potential acquisition targets, Stat reports, citing a person familiar with the companies' relationships.

Biogen Is More Likely to Be a Buyer Than Seller

Biogen Inc is working with investment bank Goldman Sachs to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

Biogen eyes potential acquisitions - Stat News

Direxion Daily S&P Biotech Bull 3X Shares

SPDR S&P Biotech ETF

The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.

3 Biotech Stocks to Buy That Are Under Severe Pressure

Shares of Biogen Inc. BIIB, -6.70% were down 0.9% in premarket trading on Thursday after Guggenheim analysts downgraded the stock to neutral, from buy. Analysts there cite the need to wait and see how the new rule proposing limited access to Biogen's Alzheimer's disease drug Aduhelm (and other drugs in the same class of treatments) to clinical trials in order to receive federal reimbursement plays out.

Guggenheim downgrades Biogen to neutral from buy after U.S. proposes limiting access to Alzheimer's drug

The stock price of Biogen Inc (NASDAQ: BIIB) fell by over 6% during intraday trading today. This is why it happened.

Biogen Stock (BIIB): Why The Price Dropped Today

Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

A proposal would mean that most Medicare beneficiaries won't have access to Biogen's Alzheimer's disease drug Aduhelm.

Why Biogen Stock Is Sinking Today

Biogen Inc.'s BIIB, -8.99% stock sank 9.3% in premarket trading on Wednesday, the day after regulators proposed limiting access to the class of Alzheimer's disease drugs that includes the company's therapy, Aduhelm.

Biogen's stock tumbles after the U.S. proposes restricting access to its Alzheimer's disease drug

Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a drug that costs $28,000 a year.

Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm

Biogen Inc (NASDAQ: BIIB) is trading lower Wednesday following a U.S. Centers For Medicare listing for "Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease." Biogen released a statement in response to the listing.

Why Biogen Shares Are Falling Today

In a rising market, two companies stood out on the downside.

Will This Stock's Pain Be Medicare's Gain?

Shares of Biogen Inc fell nearly 10% on Wednesday after the U.S. government announced limited coverage of Alzheimer's treatments including the drugmaker's Aduhelm, dealing a blow to the controversial treatment that was approved last year.

Biogen slumps after Medicare's restrictive decision on Alzheimer's drug

The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia.  However, the decision only extends to patients in a qualifying clinical trial.

CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply

Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer's drug whose benefits have been widely questioned, a major development in the nation's tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices.

Medicare limits coverage of Biogen's $28,000-a-year Alzheimer's drug

Doctors demanded the FDA revoke its approval for the Alzheimer's drug Aduhelm, which can cause side effects like brain bleeding.

Medicare Seeks To Limit Coverage For Controversial Alzheimer's Drug Aduhelm

The guidance is a blow for Biogen, which has struggled with sales of its new drug after a controversial FDA approval.

Medicare proposes limiting coverage of controversial Alzheimer's drug to people involved in clinical trials

Biogen Inc. BIIB, +2.64% shares fell more than 6% in the extended session Tuesday after the Centers for Medicare and Medicaid Services, which oversees the Medicare program, said it plans to cover the biotech's controversial Alzheimer's drug Aduhelm and future others like it only in certain instances. CMS's proposal is that Food and Drug Administration-approved monoclonal antibodies such as Aduhelm and others in its class would be covered for people with Medicare only if they are enrolled in "qualifying clinical trials," the agency said.

Biogen stock falls more than 6% after Medicare plans coverage limits for pricy Alzheimer's drug

Department of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.

News for Biogen Stock (BIIB)